As the National Pharmaceutical Pricing Authority (NPPA) gets down to revisiting the prices of stents and discussing their makers' grievances in February, here are five reasons why multinational stent companies selling relatively high-end products can still hope. 'All stents made equal' argument reopened to debate? According to a Mint newspaper report, the NPPA requested a … Continue reading Stent price control: 5 reasons why ‘high-end stent’ companies might still hope
Tag: price control
“Come into my parlour..” India’s strange #medtech pricing decisions
Correct me if I am wrong but I do believe that the Union Ministry of Health and Family Welfare just acknowledged that when prices of a product are fixed, manufacturers are discouraged from entering the market. And that competition brings down prices. Yes, you read that right, competition, and not price control. In a revealing … Continue reading “Come into my parlour..” India’s strange #medtech pricing decisions
Abbott at number one : concerns about rising drug prices
Abbott's acquisition of Piramal's Indian branded drugs unit has raised the spectre of rising prices in some quarters. The reasons are two-fold : one, Abbott will pay Rs 17,000 crore for a Rs 2000 crore business and the need to earn a decent return on this will make it raise drug prices. And two, Abbott now … Continue reading Abbott at number one : concerns about rising drug prices
Apothecurry 